Ventricular Hypertrophy Plus Neurohumoral Activation Is Necessary to Alter the Cardiac &bgr;-Adrenoceptor System in Experimental Heart Failure
作者:
Kirsten Leineweber,
Katja Brandt,
Beate Wludyka,
Anja Beilfuß,
Klaus Pönicke,
Ingrid Heinroth-Hoffmann,
Otto-Erich Brodde,
期刊:
Circulation Research: Journal of the American Heart Association
(OVID Available online 2002)
卷期:
Volume 91,
issue 11
页码: 1056-1062
ISSN:0009-7330
年代: 2002
出版商: OVID
关键词: monocrotaline;right heart hypertrophy;neurohumoral activation;&bgr;-adrenoceptor;G protein–coupled receptor kinase
数据来源: OVID
摘要:
Abstract—Treatment of rats with monocrotaline (MCT) leads to pulmonary hypertension, right ventricular (RV) hypertrophy, and finally to RV heart failure. This is associated with characteristic changes in right ventricular &bgr;-adrenoceptors (&bgr;-AR), neuronal noradrenaline transporter (NAT) density and activity (uptake1), and G protein–coupled receptor kinase (GRK) activity. This study aimed to find out factors that determine &bgr;-AR, uptake1, and GRK changes. Thus, 6-week-old rats were treated with 50 mg/kg MCT subcutaneous or 0.9% saline. Within 13 to 19 days after MCT application (group A), RV weight (222±6 versus 147±5 mg) and RV/left ventricular (LV) weight ratio (0.42±0.01 versus 0.29±0.01) were significantly increased, whereas plasma noradrenaline, RV &bgr;-AR density, RV NAT density and activity, and RV GRK activity were not significantly altered. Twenty-one to twenty-eight days after MCT (group B), however, not only RV weight (316±4 versus 148±2 mg) and RV/LV weight ratio (0.61±0.01 versus 0.3±0.01) were markedly increased but also plasma noradrenaline (645±63 versus 278±18 pg/mL); now, RV &bgr;-AR density (13.4±1.3 versus 26.5±1.1 fmol/mg protein), RV NAT density (50.9±11.3 versus 79.6±2.9 fmol/mg protein), and RV NAT activity (65.4±7.4 versus 111.8±15.9 pmol [3H]-NA/mg tissue slices/15 min) were significantly decreased and RV-membrane GRK activity (100±15 versus 67±6 [32P]-rhodopsin in cpm) significantly increased. LV parameters of MCT-treated rats were only marginally different from control LV. We conclude that in MCT-treated rats ventricular hypertrophy per se is not sufficient to cause characteristic alterations in the myocardial &bgr;-AR system often seen in heart failure; only if ventricular hypertrophy is associated with neurohumoral activation &bgr;-ARs are downregulated and GRK activity is increased.
点击下载:
PDF
(137KB)
返 回